



# *2018 ANNUAL REPORT*

## *CONTENTS*

Corporate Directory	2
Chair's Report	3
Operating and Financial Review	4
Directors' Report	5
Remuneration Report	9
Corporate Governance Statement	15
Lead Auditor's Independence Declaration	22
Consolidated Financial Statements	23
Notes to the Consolidated Financial Statements	28
Directors' Declaration	53
Independent Auditor's Report	54
NSX Additional information	57

## ***CORPORATE DIRECTORY***

**ACN 155 518 380**

### **Directors**

Kosmas Dimitriou, *Chair*

Dr George Syrmalis, *Executive Director and Chief Executive Officer*

Peter Buchanan Simpson

John Stratilas

### **Company secretary**

Gerardo Incollingo

### **Chief Executive Officer**

Dr George Syrmalis

### **Registered office**

Level 9, 85 Castlereagh Street

Sydney, NSW 2000

### **Principal place of business**

Level 9, 85 Castlereagh Street

Sydney, NSW 2000

### **Share register**

Boardroom Pty Limited

Level 12, 225 George Street

### **Auditor**

RSM Australia Partners

Level 13, 60 Castlereagh Street

Sydney NSW 2000

### **Stock exchange listings**

iQX Limited shares are listed on the National Securities Exchange (NSX:IQX).

### **Website address**

[www.iqxinvestments.com](http://www.iqxinvestments.com)

## CHAIR'S REPORT

On behalf of the board of directors, it is an honour and privilege to provide a review of iQX Limited for the financial year ended 30 June 2018.

The iQX team has successfully continued to translate the Company's strategy, into tangible deliverables including:

- The realisation of good value investment at the early stage; and
- The expansion of our infrastructure, in particular the establishment of Capial Labs, the equity crowd sourcing business unit of IQX Limited subsidiary, IQX Investment Services Pty Limited. The financial results for the year ended 30 June 2018 reflect the on-going investment and development of iQX Limited's early stage biotechnology assets.

iQX Limited is always seeking to deliver value to all its stakeholders and to ensure that we partner with the iQ Group of companies to identify and invest into sustainable early stage biotechnology investments, on a global scale in order to continue the journey of eradicating disease through capital investment.

We are confident that our entrepreneurial, curious and innovative iQX team, led by an aspirational and committed group of executive management and board members, can deliver on the clear mandate to build the iQX business and make a real difference within the Australian Life Science sector.

  
Kosmas Dimitriou  
Chair

## OPERATING AND FINANCIAL REVIEW


The Operating and Financial Review (“OFR”) is provided to assist shareholders’ understanding of the performance of iQX Limited (“iQX” or the “Company”) and its controlled entities (collectively referred to as the “Group”) and the factors underlying the Group’s results and financial position for the period 1 July 2017 to 30 June 2018.

### SUMMARY OF FINANCIAL RESULT

- Revenue reduced to \$1.8 million due to completion of licensing project in prior year;
- Loss after tax \$3.6 million
- Fair value of financial assets remains at \$19.0m
- Cash used in operations decreased by \$4.4m

\$A millions	FY18	FY17	Change
Revenue	1.8	3.4	(1.6)
Profit before tax	(3.7)	17.5	(21.2)
FV of financial assets	19.5	19.0	0.5
Cash used in operations	(4.4)	(0.9)	(3.5)

Revenue decreased by 48% to \$1.8 million in the past year as a result of an increase in capital management advisory services provided, and asset related revenue.



### OPERATING HIGHLIGHTS

- Series 8 Life Science Fund (Global) ESVCLP LP (Series 8), managed by subsidiary iQX Investment Services Pty Ltd, was granted unconditional registration from the Department of Industry, Innovation and Science as an early stage venture capital

limited partnership. The iQ Series 8 Fund is currently capped at A\$100 million;

- Capital Labs, a venture of iQX Investment Services Pty Ltd was granted a financial services license in December 2017. Capital Labs is a crowdfunding platform, linking start-up Australian biotechnology companies with retail investors in accordance with the Corporations Amendment (Crowd Sourced Funding) Act and ASIC Consultation Paper 289;
- Purchase of Capital Labs platform, for \$983,000.

### ABOUT IQX

Part of the IQ Group Global, IQX Limited is an NSX listed investment and funds management company specialising in the life science sector. Our team of experts include investment managers, physicians and scientists who are committed to eradicating disease through capital investment.

[lqxinvestments.com](http://lqxinvestments.com)

### ABOUT THE IQ GROUP GLOBAL

The iQ Group Global provides a turnkey solution for life sciences companies, spanning corporate advisory and investment banking, through to research, development, commercialisation and sales. The iQ Group Global facilitates an end to end solution along the drug lifecycle creating the medicines of tomorrow.

[theigrouppglobal.com](http://theigrouppglobal.com)

## DIRECTOR'S REPORT

The Directors present their report together with the consolidated financial statements of iQX Limited ("iQX" or the "Company") and its subsidiaries (collectively referred to as the "Group") as at and for the year ended 30 June 2018.

### DIRECTORS

The names of Directors who held office of the Company at any time during the financial year and at the date of this report, together with information on their qualifications, experience, special responsibilities, other listed company directorships and other details, are as follows.

#### **Dr George Syrmalis**

Executive Director and Group Chief Executive Officer

Appointed: 24 November 2014

*Trained in Nuclear Medicine-Radiation Immunology.*

Dr Syrmalis founded and led as CEO and Chair of The Bionuclear Group SA, (1995-2005) incorporating Antisoma SA, Bionuclear Institute of Diagnosis and Therapy SA, Bionuclear Research and Development SA, and Vitalcheck SA.

Dr Syrmalis is currently a Non-executive Director of FarmaForce Limited, a company listed on the Australian Stock Exchange; and Executive Director of iQnovate Ltd, a company listed on the National Stock Exchange of Australia.

#### **Kosmas Dimitriou**

Non-Executive Director and Chair

Appointed: 20 November 2012

*Bachelor Commerce Laws (University of Western Sydney), Diploma of Legal practice (Tax) (University of Sydney)*

Kosmas is a tax lawyer with over 18 years' experience in taxation, holding senior roles in the profession and commerce. Kosmas also advises the government and ATO on tax policy and tax law design.

Mr Dimitriou is currently a Non-Executive Director of iQ3Corp Ltd, a company listed on the Australian Stock Exchange.

Mr Dimitriou serves as a member of the Remuneration and Nomination Committee, and the Audit and Risk Management Committee, for iQX Limited.

#### **Peter Simpson**

Non-Executive Director

Appointed: 14 August 2013

*Masters of Pharmacy*

Mr Simpson has extensive experience in the pharmaceutical industry and has been involved in the development of pharmaceutical products for both the Australian and international markets. For eight years he was the Research and Development Manager at David Bull Laboratories and oversaw the development and approval of over 80 products in the Australian, UK and US markets.

Mr Simpson is currently a Non-Executive Director of iQnovate Ltd, a company listed on the National Stock Exchange of Australia.

#### **John Stratilas**

Independent Non-Executive Director

Appointed: 6 February 2012

Mr Stratilas brings to the Board over 20 years of experience in operating a number of businesses in the food industry and commercial property development and management markets.

Mr Stratilas serves as a member of the Remuneration and Nomination Committee, and the Audit and Risk Management Committee, for iQX Limited.

## COMPANY SECRETARY

### Gerardo Incollingo

Gerardo was appointed Company Secretary on 22 August 2016. Gerardo is Managing Director of LCI Partner's, a firm of accountants.

## PRINCIPAL ACTIVITIES

During the year the principal activity for the Group consisted of general investing activities and exploring investment opportunities in the Life Science industry.

## DIVIDENDS

No dividends have been paid or declared since the end of the previous financial year, nor do the directors recommend the declaration of a dividend.

## REVIEW OF OPERATIONS

Information on the operations and financial position of the Group and its business strategies and prospects is set out in the operating and financial review ("OFR") on page 4 of this Annual Report.

Information in the OFR is provided to enable shareholders to make an informed assessment about the Group's strategies and prospects for future financial years. Details that could give rise to likely material detriment to the Group (for example, information that is commercially sensitive, is confidential or could give a third party commercial advantage) has not been included.

## SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

There have been no significant changes in the state of affairs of the Company during the year.

## SIGNIFICANT EVENTS AFTER THE BALANCE DATE

There have been no significant events occurring after the balance date which may affect the Group's operations or results of those operations or the Group's state of affairs.

## LIKELY DEVELOPMENTS AND EXPECTED RESULTS OF OPERATIONS

Likely developments in the operations of the Group and the expected results of those operations in future financial years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Group.

## ENVIRONMENTAL REGULATION

The Directors recognise the importance of environmental and workplace health and safety issues. The Directors are committed to compliance with all relevant laws and regulations to ensure the protection of the environment, the community and the health and safety of employees.

The operations of the Group are not subject to any particular and significant environmental regulation under the laws of the Commonwealth of Australia or any of its states or territories.

Based on results of enquiries made, the Board is not aware of any significant breaches of environmental regulations during the period covered by this report.

## REMUNERATION REPORT

The Remuneration Report is set out on pages 9 to 14 and forms part of the Directors' Report for the year ended 30 June 2018.

## PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the *Corporations Act 2001*.

## INDEMNIFICATION OF AUDITORS

The Company has not, during or since the end of the financial year ended 30 June 2018, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor. During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

### NON-AUDIT SERVICES

Details of the amounts paid to the auditor of the Company, RSM Australia and its network firms for audit and non-audit services provided during the year ended 30 June 2018 are disclosed in note 26 of the consolidated financial statements.

### AUDITOR INDEPENDENCE

The auditor's independence declaration is set out on page 22 and forms part of the Directors' Report for the year ended 30 June 2018.

### MEETINGS OF DIRECTORS

The number of Directors' meetings held (including meetings of committees of the Board) and number of meetings attended by each of the Directors of the Company during the financial year are:

Director	Full meetings of directors		Meetings of committees			
			Audit & Risk Management		Remuneration & Nomination	
	A	B	A	B	A	B
Dr George Syrmalis	9	9	-	-	-	-
Kosmas Dimitriou	9	9	1	1	1	1
Peter Simpson	9	8	-	-	-	-
John Stratilas	9	9	1	1	1	1

A – Eligible to attend

B - Attended

### DIRECTORS INTERESTS

The relevant interests of each Director in the equity of the Company at the date of this report are set out in the following table.

Director	Number of Ordinary Shares	Number of Options over Ordinary Shares	Number of additional Ordinary Shares subject to escrow
Dr George Syrmalis	16,117,112	-	-
Kosmas Dimitriou	-	-	-
Peter Simpson	-	-	-
John Stratilas	1,600,000	-	-

### INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS


The Company has, during the financial year, paid an insurance premium in respect of an insurance policy for the benefit of the Company and those named and referred to above including the directors, company secretaries, officers and certain employees of the Company and related bodies corporate as defined in the insurance policy. The insurance is appropriate pursuant to section 199B of the Corporates Act 2001.

In accordance with commercial practice, the insurance policy prohibits disclosure of the terms of the policy, including the nature of the liability insured against and the amount of the premium.

ROUNDING OF AMOUNTS

The amounts in the consolidated financial statements have been rounded off to the nearest dollar in accordance with ASIC Corporation Instrument 2016/191.

The Directors' Report is signed in accordance with a resolution of the Directors.



Dr. George Syrmalis

*Executive Director and Chief Executive Officer*

Sydney

28 September 2018

## REMUNERATION REPORT (AUDITED)

This remuneration report outlines the remuneration arrangements for Non-Executive Directors, Executive Directors and other Key Management Personnel (“KMP”) of the Company for the financial year ended 30 June 2018. The information in this report has been audited as required by section 308(3C) of the *Corporations Act 2001*.

The report is presented under the following sections:

1. Key management personnel (KMP) covered in this report
2. Remuneration governance
3. Executive KMP remuneration arrangements
  - A. Remuneration principles and strategy
  - B. Detail of incentive plans
4. Executive KMP remuneration outcomes (including link to performance)
5. Executive KMP contractual arrangements
6. Non-executive director arrangements
7. Additional disclosures relating to options and shares

### 1. KEY MANAGEMENT PERSONNEL

The table below outlines the KMP at any time during the financial year, and unless otherwise indicated, they were KMP for the entire year.

Name	Position	Term as KMP
<b>Non-Executive Directors</b>		
Kosmas Dimitriou	Chair	Entire year
John Stratilas	Non-Executive Director	Entire year
Peter Simpson	Non-Executive Director	Entire year
<b>Executive Directors</b>		
Dr George Syrmalis	Executive Director and Group CEO	Entire year
<b>Other Executive KMP</b>		
Spiro Sakiris	Group Chief Financial and Operating Officer	Until 4 December 2017

### 2. REMUNERATION GOVERNANCE

The Board has established a remuneration and nomination committee (“RNC”) which is currently comprised of the following members:

Committee member	Position	Independent
Kosmas Dimitriou	Member	No
John Stratilas	Member	Yes

The key responsibility of the RNC is to assist the Board in its oversight of:

- the remuneration framework and policy for Executive and employee reward;
- the determination of appropriate Executive reward, including advice on structure, quantum and mix;
- the determination of achievement of performance measures included in any variable remuneration plan;
- compliance with applicable legal and regulatory requirements; and
- board size, composition and succession planning.

A full charter outlining the RNC’s responsibilities is available at: [www.iqxinvestments.com/](http://www.iqxinvestments.com/)

### 3. EXECUTIVE KMP REMUNERATION ARRANGEMENTS

#### 3A Remuneration principles and strategy

In FY18 the executive remuneration framework consisted of fixed remuneration and short and long-term incentives as outlined below. The Company aims to reward executives with a level and mix of remuneration appropriate to their position, responsibilities and performance within the Company and aligned with market practice. Remuneration levels are considered annually through a remuneration review which considers market data and the performance of the Company and individual.

#### 3B Detail of incentive plans

##### Short-term incentive (STI)

The Company operates an annual STI program available to executives and awards a cash incentive subject to the attainment of clearly defined key performance measures.

A summary of the Executive STI plan in effect during FY18 is provided below:

Who participates?	Dr George Syrmalis and Spiro Sakiris
How is STI delivered?	Cash
What is the STI opportunity?	Up to 25% of base salary
What are the performance conditions for FY18?	Individual performance goals against annual plans.
How is performance assessed?	On an annual basis, after consideration of performance against key performance indicators (KPI).

##### Employee benefit plan (EBP)

The following table explains the key features of the Employee Benefit Plan. Dr George Syrmalis and Spiro Sakiris are eligible to receive 153,000 and 90,000 performance rights respectively per annum under the EBP.

Who participates?	All employees of the Group.
How are Long Term Incentives delivered?	Entitlement to shares and performance rights.
What are the performance conditions for the FY18 grant?	Individual performance goals against annual plans.
How is performance assessed?	At the end of the relevant performance period, the Company will determine whether and to what extent the participant has satisfied the applicable performance criteria.
When does the award vest?	Awards vest after a total of three years' continual service following achievement of the applicable performance criteria.
How are grants treated on termination?	The participant must be a current employee at vesting date in order to be entitled to shares.
How are grants treated if a change of control occurs?	If a takeover bid or other offer is made to acquire some or all of the issued shares of the Company, participants will generally be entitled to request that all performance rights vest immediately, regardless of whether the relevant performance conditions have been satisfied.

#### 4. EXECUTIVE KMP REMUNERATION OUTCOMES FOR 2018

##### Group performance and its link to STI

Key Performance Indicators (KPIs) are set annually, with a certain level of consultation with KMP. The measures are specifically tailored to the area each individual is involved in and has a level of control over. The KPI's target areas the Company believes hold greater potential for group expansion and profit, covering financial and non-financial as well as short-term and long-term goals. The level set for each KPI is based on budgeted figures for the Company and respective industry standards.

The table below provides a summary of the Company's performance in FY18. The information below is taken into account by the Board when setting and determining short-term and long-term remuneration for KMP.

Short-term incentive payments or EBP awards were made in the period to 30 June 2018 (see table below for details). No short-term incentive payments or EBP awards were made in the period 30 June 2017.

No LTI payments were made in, or provided for during, the period to 30 June 2018 or 30 June 2017.

Share performance				Earnings performance A\$ million	
Period	Closing share price at 30 June	Dividend per share	EPS (cents)	Revenue	Profit/(loss) after tax
FY2018	\$0.32	NIL	(2.93)	\$1.8	(\$3.6)
FY2017	\$0.40	NIL	12.22	\$3.4	\$14.2
FY2016	\$0.43	NIL	(2.26)	\$0.5	(\$2.3)
FY2015	\$0.65	NIL	(1.27)	\$0.8	(\$1.3)
FY2014	\$0.65	NIL	(1.38)	-	(\$1.2)

##### Executive KMP remuneration disclosure for the year ended 30

##### June 2018

The following table of executive KMP remuneration has been prepared in accordance with accounting standards and the *Corporations Act 2001* requirements, for the period 1 July 2017 to 30 June 2018.

KMP		Short Term				Post employment	Share based payments		Total	
Name	Year	Base salary	Cash bonus	Non-cash benefit	Other	Super-annuation	Options	Shares	Total	Performance related %
Dr George Syrmalis	2018	333,984	105,469	-	22,831	43,917	-	3,060	509,261	21%
	2017	300,180	-	-	-	26,719	-	-	326,899	0%
Spiro Sakiris	2018	96,875	56,250	-	-	14,547	-	900	168,572	33%
	2017	160,096	-	6,240	24,998	16,623	-	-	207,957	0%
<b>Total Executive KMP</b>	<b>2018</b>	<b>430,859</b>	<b>161,719</b>	<b>-</b>	<b>22,831</b>	<b>58,464</b>	<b>-</b>	<b>3,960</b>	<b>677,833</b>	<b>24%</b>
	<b>2017</b>	<b>460,276</b>	<b>-</b>	<b>6,240</b>	<b>24,998</b>	<b>43,342</b>	<b>-</b>	<b>-</b>	<b>534,856</b>	<b>0%</b>

##### Share based payments

Mr Syrmalis was issued with 306,000 fully paid ordinary shares for meeting his individual performance goals for the periods FY 2013 to FY2014 inclusive. The shares were issued at \$0.01 per share. Shares were issued 28 March 2018.

#### 4. EXECUTIVE KMP REMUNERATION OUTCOMES FOR 2018 (CONTINUED)

Mr Sakiris was issued with 90,000 fully paid ordinary shares for meeting his individual performance goals for the period FY2014. The shares were issued at \$0.01 per share. Shares were issued 28 March 2018.

##### Cash Bonuses

Mr Syrmalis was paid \$105,469 in cash bonuses for meeting agreed individual performance goals. The payments relates to the periods FY2015 to FY2017 inclusive.

Mr Sakiris was paid \$56,250 in cash bonuses for meeting agreed individual performance goals. The payments relates to the periods FY2015 to FT2017 inclusive.

#### 5. EXECUTIVE KMP CONTRACTUAL ARRANGEMENTS

Remuneration arrangements for executive KMP are formalised in employment agreements. The key terms and conditions of executive employment agreements for the year ended 30 June 2018 are outlined in the table below.

Executive	Position	Effective date	Fixed annual remuneration <sup>1</sup>	Term	Notice period <sup>2</sup>	Termination payment
Dr George Syrmalis	Group Chief Executive Officer	1 October 2017	\$383,906	Ongoing	6 months	Superannuation will be paid irrespective of the termination benefits cap under the Corporations Act.

<sup>1</sup> Fixed Annual Remuneration includes base salary plus superannuation contributions in accordance with Superannuation Guarantee legislation.

<sup>2</sup> The Company may terminate employment immediately and without notice in certain circumstances, including where the executive has committed a serious or persistent breach of their employment agreement or where the executive has been dishonest or fraudulent in the course of performing their duties.

#### 6. NON-EXECUTIVE DIRECTOR ARRANGEMENTS

##### Determination of fees and maximum aggregate

##### NED fee pool

The Constitution of the Company provides that non-executive directors, other than a Managing Director or an Executive Director, are entitled to director's fees as determined by the Directors, but not exceeding in aggregate for any financial year, the maximum sum that is from time to time approved by the Company in General Meeting. At the date of this report this maximum sum is \$300,000 (inclusive of superannuation).

##### Fee policy

NED fees consist of base fees and committee fees. The payment of committee fees recognises the additional time commitment required by NEDs who serve on board committees. Directors who also chair the Audit and Risk Management Committee shall be entitled to an additional fee of \$5,000 (including superannuation) per annum. The chair of the board attends all committee meetings but does not receive any additional committee fees in addition to base fees.

NEDs may be reimbursed for expenses reasonably incurred in attending to the Company's affairs. NEDs do not receive retirement benefits, nor do they participate in any incentive programs.

## 6. NON-EXECUTIVE DIRECTOR ARRANGEMENTS (CONTINUED)

### Statutory remuneration table for FY18

The table below sets out the elements of NED fees and other benefits provided during 2018.

Fees applicable for 2018	Chair	Member
Board	\$40,000	\$40,000
Audit and Risk Management Committee	\$5,000	Nil
Remuneration and Nomination Committee	Nil	Nil
Superannuation	Included in above amounts.	
Other	Reimbursement of travel and other expenses necessarily incurred in exercising their duties	

### Non-executive remuneration disclosure for the year ended 30 June 2018

The following table of non-executive remuneration has been prepared in accordance with accounting standards and the *Corporations Act 2001* requirements, for the period 1 July 2017 to 30 June 2018. All amounts are in AUD.

NED	Year	Board fees	Other fees	Non-cash benefit	Super-annuation	Total	Performance Related %
Kosmas	2018	36,602	-	-	3,477	40,079	0%
Dimitriou	2017	32,109	-	-	3,050	35,159	0%
Peter	2018	34,319	-	-	3,260	37,579	0%
Simpson	2017	32,109	4,566	-	3,484	40,159	0%
John Stratilas	2018	34,319	-	-	3,260	37,579	0%
	2017	32,109	-	-	3,050	35,159	0%
<b>Total NED</b>	<b>2018</b>	<b>105,240</b>	<b>-</b>	<b>-</b>	<b>9,997</b>	<b>115,237</b>	<b>0%</b>
	<b>2017</b>	<b>96,327</b>	<b>4,566</b>	<b>-</b>	<b>9,584</b>	<b>110,477</b>	<b>0%</b>

## 7. ADDITIONAL DISCLOSURES RELATING TO OPTIONS AND SHARES

### Movements in Equity Holdings of KMP

The following table sets out the movement during the reporting period in the number of ordinary shares in IQX Limited held directly, indirectly, or beneficially by KMP including their related parties.

KMP	Held at 1 July 2017	Granted as remuneration	Options exercised	Net change other	Forfeited	Held at 30 June 2018
<b>Non-executive Directors</b>						
Kosmas Dimitriou	-	-	-	-	-	-
Peter Simpson	-	-	-	-	-	-
John Stratilas	1,600,000	-	-	-	-	1,600,000
<b>Executive Directors</b>						
Dr George Syrmalis	15,811,112	306,000	-	-	-	16,117,112
<b>Other Executive KMP</b>						
Spiro Sakiris	2,362,630	90,000	-	-	-	2,452,630
<b>Total KMP</b>	<b>19,773,742</b>	<b>396,000</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>20,169,742</b>

## 7. ADDITIONAL DISCLOSURES RELATING TO OPTIONS AND SHARES (CONTINUED)

### Movements in Other Equity Holdings of KMP

The following table sets out the movement during the reporting period in the number of Options in iQX Limited held directly, indirectly, or beneficially by KMP including their related parties.

KMP	Held at 1 July 2017	Granted as remuneration	Vested	Other	Forfeited	Held at 30 June 2018
<b>Non-executive Directors</b>						
Peter Simpson	-	-	-	-	-	-
<b>Executive Directors</b>						
George Syrmalis	-	-	-	-	-	-
Con Tsigounis	-	-	-	-	-	-
<b>Other Executive KMP</b>						
Spiro Sakiris	-	-	-	-	-	-
<b>Total KMP</b>	-	-	-	-	-	-

### Performance rights table

	Remuneration type	Grant date	Grant Value	% Vested /paid during year	Expiry date for vesting or payment
<b>Executive Directors</b>					
George Syrmalis	Shares	1/4/2015	1,530	100%	31/3/2018
George Syrmalis	Shares	1/4/2016	1,530	-	31/3/2019
George Syrmalis	Shares	1/4/2017	1,530	-	31/3/2020
George Syrmalis	Shares	1/4/2018	1,530	-	31/3/2021

Reason for grant – Performance rights

All grants are in accordance with the Employee Share Scheme (ESS)

## CORPORATE GOVERNANCE STATEMENT

The Board is committed to achieving and demonstrating the highest standards of corporate governance. The Board continues to refine and improve the governance framework and practices in place to ensure they meet the interests of shareholders. The Company's corporate governance policies and procedures comply with Annexure 1 of the National Securities Exchange of Australia (NSX) Practice Note 14. In addition, the Company's corporate governance policies and procedures also incorporate those recommendations referred to in the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations (the Principles).

### Principal 1: Lay solid foundations for management

#### Role of the Board and Management

The Board of Directors is responsible for the corporate governance of the Company. The Board provides strategic guidance for the Company, and effective oversight of management. The Board guides and monitors the business and affairs of the Group on behalf of the shareholders by whom they are elected and to whom they are accountable.

The Board has delegated responsibility for day-to-day management of the Company to the Chief Executive Officer (CEO) and there is a formal delegations structure in place which sets out the powers delegated to the CEO and those specifically retained by the Board, these delegations are reviewed on a regular basis.

#### Responsibilities of the Board

The Board is responsible for:

- Overseeing the company, including its control and accountability systems;
- Overseeing the integrity of the accounting and corporate systems, including external audit;
- Appointing and removing the CEO/Managing Director;
- Where appropriate, ratifying the appointment and removal of senior executives;
- Providing input into and final approval of management's development of corporate strategy and performance objectives;
- Reviewing, ratifying and monitoring systems of risk management and internal controls, codes of conduct and legal compliance;

- Monitoring senior executives' performance and implementation of strategy;
- Ensuring timely and balanced disclosure of all material information concerning the company that a reasonable person would expect to have a material effect on the price or value of the company's securities;
- Ensuring appropriate resources are available to senior executives;
- Approving and monitoring the operating budgets and progress of major capital expenditure, capital management and acquisitions and divestures; and
- Monitoring the effectiveness of the entity's governance practices.

#### Allocation of individual responsibilities

Formal letters of appointment are provided to all new Directors and Senior Executives setting out key terms and conditions of their appointment.

#### Responsibilities of management

Management are responsible for implementing the strategic objectives of the Company and operating within the risk appetite set by the Board as well as other aspects of the day-to-day running of the Company.

Management is also responsible for providing the Board with accurate, timely clear information to enable the Board to perform its responsibilities.

#### Induction

All new Directors participate in a formal induction process co-ordinated by the Company Secretary. This induction process includes briefings on the Company's financial, strategic, operational and risk management position, the Company's governance framework and key developments in the Company and the industry and environment in which it operates.

#### Role and accountability of the Company Secretary

The Company Secretary is appointed by the Board and is responsible for:

- Advising the Board and its Committees on Governance matters;
- Monitoring compliance with Board policies and procedures;
- Co-ordinating Board papers;

- Accurately recording decisions and discussions from board meetings; and
- Co-ordinating the induction and professional development of Directors.

In addition to the above responsibilities, the Company Secretary, played an integral role in assisting with the conduct and processes of the Board, as well as the dispatch of material to the Board members.

#### **Ongoing training**

Directors identify additional training needs on an ongoing basis and attend these as necessary to ensure they have the appropriate skills and knowledge to perform their role.

#### **Appointment of Board Members**

Prior to appointing or putting forward a candidate for election to the Board, appropriate checks such as character, experience, criminal records and education are performed. All material information in the Company's possession is provided to security holders to allow them to make an informed decision about the suitability of the candidate at the Company's next Annual General Meeting of shareholders.

#### **Principle 2: Structure the Board to add value**

The Board's policy is that the Board needs to have an appropriate mix of skills, experience, expertise and diversity to be well equipped to help the Company navigate the range of challenges it faces.

The names, independence status, terms of service, experience, expertise and qualifications, of the members of the Board as at the date of this report are set out in the Director's Report.

The Company does not have a majority independent directors. The Board considers this to be satisfactory considering the size and complexity of the business.

#### **Composition of the Board**

The Board's composition is determined based on criteria set out in the Company's constitution and the Board Charter.

The Board seeks to ensure that:

- At any point in time, its membership represents an appropriate balance between directors with experience and knowledge of the Company and Directors with an external or fresh perspective;
- There is a sufficient number of directors to serve on Board committees without overburdening the Directors or making it difficult for them to fully discharge their responsibilities; and

- The size of the Board is appropriate to facilitate effective discussion and efficient decision making.

In accordance with the NSX Listing Rules, the Company must hold an election of Directors each year.

#### **Board committees**

To ensure that the responsibilities of the Board are upheld and executed to the highest level, the Board has established the following Board committees:

- Audit and Risk Committee
- Remuneration and Nomination Committee

Each of these committees has established charters and operating procedures in place, which are reviewed on a regular basis. The Board may establish other committees from time to time to deal with matters of special importance. The Committees have access to the Company's executives and senior management as well as independent advice. Copies of the minutes of each Committee meeting are made available to the full Board, and the Chairman of each Committee provides an update on the outcomes at the Board meeting that immediately follows the Committee meeting.

#### **Board skills matrix**

The key skills required by the Board are highlighted in the matrix below, the Board believes that there are sufficient Directors with these skills and there are no deficiencies in these skills in the current board.

- Risk and compliance: Identify key risks to the Company related to each key areas of operations. Ability to monitor risk and compliance and knowledge of legal and regulatory requirements.
- Financial and Audit: Experience in accounting and finance to analyse statements, assess financial viability, contribute to financial planning, oversee budgets and funding arrangements.

Strategy: Ability to identify and critically assess strategic opportunities and threats to the organisation. Develop strategies in context to our policies and business objectives.

- Policy development: Ability to identify key issues for the organisation and develop appropriate policy parameters within which the Company should operate.

#### **Independent decision making**

The Board recognises the important contribution independent Directors make to good corporate governance. All Directors, whether independent or not, are required to act in the best interests of the Company and to exercise unfettered and independent judgment.

A Director is considered to be independent if he or she is free of any interest, position, association or relationship that might influence or reasonably be perceived to influence, in a material respect, his or her capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the Company and its security holders generally.

If any Director believes there is a change in their independence status, they are required to notify the Board as soon as possible.

The Board has adopted specific principles in relation to Directors' independence and considers the following, at least annually, when determining if a Director is independent. Whether the Director:

- Is a substantial shareholder of the company or an officer of, or otherwise associated directly with, a substantial shareholder of the company.
- Is employed, or has previously been employed in an executive capacity by the company or another group member, and there has not been a period of at least three years between ceasing such employment and serving on the Board.
- Has within the last three years been a principal of a material professional adviser or a material consultant to the Company or another group member, or an employee materially associated with the service provided.
- Is a material supplier or customer of the Company or other group member, or an officer of or otherwise associated directly or indirectly with a material supplier or customer.

- Has a material contractual relationship with the Company or another group member other than as a Director.

#### **Role of the Chair**

The Chairman of the Board is responsible for leadership of the Board and for the efficient organisation and conduct of the Board's functioning.

The Chairman facilitates the effective contribution of all directors and promotes constructive and respectful relations between directors and between Board and management.

#### **Nomination Committee**

The Nomination Committee meets as required during the year to assist the Board in fulfilling its corporate governance responsibilities in regard to:

- Board appointments, re-elections and performance and general succession planning for Board / Senior Management;
- Directors' induction and continuing development;
- Board Committee membership; and
- Endorsement of Executive appointments.

The Nomination Committee's Charter sets out the Committee's responsibilities, which include making recommendations to the Board on the appropriate skill mix, personal qualities, expertise and diversity of each position following the annual assessment of the Board. When a vacancy exists or there is a need for particular skills, the Committee, in consultation with the Board, determines the selection criteria based on the skills deemed necessary. Board appointees must stand for election at the next Annual General Meeting of shareholders.

The Committee also makes recommendations to the Board and oversees implementation of the procedure for evaluating the Board's performance.

#### **Access to information**

The Board is provided with the information it needs to discharge its responsibilities effectively and all Directors have complete access to senior management through the CEO or Company Secretary.

In certain circumstances, each Director has the right to seek independent professional advice at the

Company's expense, within specified limits, or with the prior approval of the Board.

### Principle 3: Act ethically and responsibly

#### Code of conduct

The Company's Corporate Ethics Policy and Corporate Code of Conduct sets out the behaviour required of Directors, employees and contractors as appropriate and include the observance of legal and other compliance obligations that relate to the company's activities from time to time. The Board acknowledges and emphasises the importance of all Directors and employees maintaining the highest standards of corporate governance practice and ethical conduct.

A Corporate Code of Conduct has been established requiring Directors and employees to:

- Act in the best interest of the entity;
- Act honestly and with high standards of personal integrity;
- Exercise due care and diligence in fulfilling the functions of office;
- Avoid conflicts and make full disclosure of any possible conflicts of interest;
- Comply with the laws and regulations that apply to the entity and its operations;
- Not knowingly participate in any illegal or unethical activity; and
- Comply with the share trading policy outlined in the Code of Conduct.

A Corporate Governance Charter and Board Charter has been adopted which regulates the duties of Directors and their dealings with the Company (including the trading of shares in the company) both internally and externally.

### Principle 4: Safeguard integrity in corporate reporting

#### Audit and Risk Management Committee

The Audit and Risk Committee assists the Board in fulfilling its corporate governance responsibilities in regards to:

- The adequacy of the entity's corporate reporting processes;
- Whether the entity's financial statements reflect the understanding of the committee members of, and otherwise provide a true and fair view

of, the financial position and performance of the entity;

- The appropriateness of the accounting judgements or choices exercised by management in preparing the entity's financial statements;
- The appointment or removal, rotation, independence and performance of the external auditor;
- The scope and adequacy of the external audit and any non-audit services;
- If, and when, the Company establishes an internal audit function:
  - the appointment or removal of the head of internal audit;
  - the scope and adequacy of the internal audit work plan; and
  - the objectivity and performance of the internal audit function.

The members of the Audit and Risk Committee throughout the Reporting Period were:

Name	Executive/Non-Executive	Independent?
Kosmas Dimitriou	Non-Executive	No
John Stratilas	Non-Executive	Yes

Accordingly, the Company does not have a majority of independent committee members. The Board considers this to be appropriate considering the size and complexity of the business.

The qualifications and experience of the Audit and Risk Committee members and their attendance at Committee meetings is included in the directors' report.

The Audit and Risk Committee reports to the full Board after every meeting on all matters relevant to the committee's roles and responsibilities.

### External auditor

The Audit and Risk Committee oversees the relationship with the external auditor. In accordance with the Corporations Act 2001, the lead Audit Partner on the audit is required to rotate at the completion of a 5- year term.

The external auditor attends the AGM and is available to answer your shareholder questions about the conduct of the audit and the preparation and content of the auditor's report.

The Board have received from its Chief Executive Officer and Chief Financial Officer a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the Company and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

### Internal control

The Board is responsible for reviewing the Company's policies on risk oversight and management and satisfying itself that management has developed and implemented a sound system of risk management and internal control.

The Board has received assurance from the Chief Executive Officer and the Chief Operating Officer that the declaration provided in accordance with section 295A of the Corporations Act 2001 is founded on a system of risk management and internal control and that the system is operating effectively in all material respects in relation to financial reporting risks.

### Principle 5: Make timely and balanced disclosure

iQX Limited has established policies and procedures to ensure timely and balanced disclosures of all material matters concerning the Company, and to ensure that all investors have equal and timely access to information on the Company's financial performance.

These policies and procedures include a comprehensive disclosure policy that includes identification of matters that may have a material effect on the price on the Company's securities,

quality control procedures over announcements, notifying them to the NSX, posting relevant information on the Company's website and issuing media releases.

The Annual Report includes relevant information about the operations of the Company during the year, key financial information, changes in the state of affairs and indications of future developments. The Annual Reports for the current year and for previous years are available under the Investor Relations section of the company website.

The half year and full year financial results are announced to the NSX and are available to shareholders via the Company and NSX websites.

All announcements made to the market, and related information (including presentations to investors and information provided to analysts or the media during briefings) are made available to all shareholders under the investor relations section of the Company website after they are released to the NSX. All NSX announcements, media releases and financial information are available on Company website within one day of public release.

### Principle 6: Respect the rights of security holders

The Company Secretary has been nominated as the person responsible for communications with the NSX.

All Executive Management have an ongoing obligation to advise the Company Secretary of any material non-public information which may need to be communicated to the market.

The Company has an Investor Relations Program which promotes effective communication with shareholders, encourages participation at general meetings and encourages communications throughout the year.

The Company engages with its security holders through:

- Giving them ready access to information about the entity and its governance via the Company website;
- Communicating openly and honestly with them;
- Encouraging and facilitating their participation in meetings of security holders; and

- Providing an email address and telephone number on all communication for security holders who wish to contact the Company.

The Company makes all NSX announcements available via its website. In addition, shareholders who are registered receive email notification of announcements.

The Notice of Annual General Meeting (AGM) will be provided to all shareholders and posted on the company's website. Notices for general meetings and other communications with shareholders are drafted to ensure that they are honest, accurate and not misleading and that the nature of the business of the meeting is clearly stated and explained where necessary.

The Board encourages full participation by shareholders at the Annual General Meeting to ensure a high level of Director accountability to shareholders and shareholder identification with the Company's strategy and goals.

An AGM question form will accompany the Notice of Meeting, giving shareholders the opportunity to forward questions and comments to the Company prior to the AGM. The external auditor is available to answer questions at the AGM.

#### Principle 7: Recognise and manage risk

The Board considers identification and management of key risks associated with the business as vital to maximize shareholder wealth. A yearly assessment of the business's risk profile is undertaken and reviewed by the Board, covering all aspects of the business from the operational level through to strategic level risks.

The CEO has been delegated the task of implementing internal controls to identify and manage risks for which the Audit and Risk Management Committee and the Board provides oversight. The effectiveness of these controls is monitored and reviewed regularly. The recent economic environment has emphasised the importance of managing and reassessing its key business risks.

The Board is responsible for reviewing the company's policies on risk oversight and management and satisfying itself that management has developed and implemented a

sound system of risk management and internal control.

The Board requires management to design and implement the risk management and internal control system to manage the Company's material business risks and report to it on whether those risks are being managed effectively.

The Company does not presently have an internal audit function. The evaluation of the risk management and internal control process is the responsibility of the Audit and Risk Management Committee and is performed in conjunction with senior executives. External consultants may be used in certain circumstances, however have not been used during the financial year.

#### Principle 8: Remunerate fairly and responsibly

The Company's remuneration policy is designed in such as a way that it:

- Motivates senior executives to pursue the long-term growth and success of the Company; and
- Demonstrates a clear relationship between senior executives' performance and remuneration.

The remuneration policy, which sets out the remuneration framework for the key management personnel (KMP) was developed by the Remuneration and Nomination Committee after seeking professional advice from independent consultants and was approved by the Board.

All executives receive a base salary, superannuation, fringe benefits, performance incentives and retirement benefits. The Remuneration and Nomination Committee reviews executive remuneration policies and practices to ensure that executive packages are referable to company performance, its executives' performance, comparable information from industry sectors and other listed corporations and independent advice. The performance of executives is measured against criteria agreed half yearly which are based on the forecast growth of the company and shareholder value. The policy is designed to attract the highest calibre executives and reward them for performance which results in long-term growth in shareholder value.

The Board expects that the remuneration structure implemented will result in the Company

being able to attract and retain the best executives. It will also provide executives with the necessary incentives to achieve long-term growth in shareholder value.

The Company's policies and practices surrounding the payment of bonuses, options and other incentive payments are reviewed by the Remuneration and Nomination Committee annually as part of the review of executive remuneration policies and practices and a recommendation is put to the Board for approval. All bonuses, options and incentives must be linked to predetermined performance criteria.

Further information about the Company's remuneration strategy and policies and their relationship to Company performance can be found in the Remuneration Report which forms part of the Directors' Report, together with details of the remuneration paid to key management personnel.

#### **Remuneration Committee**

The responsibilities of the Remuneration and Nomination Committee include a review of and recommendation to the Board on:

- The company's remuneration, recruitment, retention and termination policies and procedures for senior executives;
- Senior executives' remuneration and incentives;
- Superannuation arrangements; and
- The remuneration framework for directors.

Each member of the Remuneration and Nomination Committee:

- Is familiar with the legal and regulatory disclosure requirements in relation to remuneration; and
- Has adequate knowledge of executive remuneration issues, including executive retention and termination policies and short term and long term incentive arrangements.

The members of the Remuneration and Nomination Committee throughout the Reporting Period were as set out in the Remuneration Report which is part of the Directors' Report.

The Company does not have a majority of independent committee members, as the Board

considers this to be satisfactory considering the size and complexity of the business.

**RSM Australia Partners**

Level 13, 60 Castlereagh Street Sydney NSW 2000  
GPO Box 5138 Sydney NSW 2001

T +61 (0) 2 8226 4500  
F +61 (0) 2 8226 4501

[www.rsm.com.au](http://www.rsm.com.au)

**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the audit of the financial report of IQX Limited for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (ii) any applicable code of professional conduct in relation to the audit.

RSM

**RSM AUSTRALIA PARTNERS**

David Talbot

**David Talbot**  
Partner

Sydney, NSW  
Dated: 28 September 2018

**IQX LIMITED AND CONTROLLED ENTITIES**  
**CONSOLIDATED STATEMENT PROFIT OR LOSS**  
**FOR THE YEAR ENDED 30 JUNE 2018**

<i>In dollars</i>	<i>Note</i>	<b>2018</b>	<b>2017</b>
Revenue	6	1,760,036	3,400,230
Other income	7(a)	74,293	19,003,522
Employee benefits expense	7(c)	(1,879,672)	(1,468,779)
Depreciation and amortisation expense		(113,265)	(71,150)
Impairment of intangible assets		(369,266)	-
Consultancy fees		(210,244)	(856,309)
Occupancy costs		(960,640)	(516,695)
Other expenses	7(d)	(1,437,649)	(1,492,717)
Share option expense		(3,960)	-
Finance costs	7(b)	(504,982)	(448,017)
Share of loss of associated companies	20	(28,653)	(57,959)
<b>(Loss)/profit before income tax</b>		<b>(3,674,002)</b>	<b>17,492,126</b>
Income tax expense	9	65,112	(3,273,739)
<b>Net (loss)/profit for the period</b>		<b>(3,608,890)</b>	<b>14,218,387</b>

**(Loss)/profit per share for the period attributable to the ordinary equity holders of the Company:**

Basic (loss)/profit per share (cents per share)	18	(2.93)	12.22
Diluted (loss)/profit per share (cents per share)	18	(2.93)	12.22

*The above interim consolidated statements of profit or loss should be read in conjunction with the accompanying notes to the consolidated financial statements.*

**IQX LIMITED AND CONTROLLED ENTITIES**  
**CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 30 JUNE 2018**

<i>0In dollars</i>	<i>Note</i>	<b>2018</b>	<b>2017</b>
<b>Net (loss)/profit for the period</b>		<b>(3,608,890)</b>	<b>14,218,387</b>
<b>Other comprehensive income</b>			
Items that are or may be reclassified subsequently to profit or loss when specific conditions are met:		-	-
<b>Other comprehensive profit/(loss) for the period, net of tax</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive (loss)/profit for the period</b>		<b>(3,608,890)</b>	<b>14,218,387</b>

*The above consolidated statements of comprehensive income, should be read in conjunction with the accompanying notes to the consolidated financial statements.*

**IQX LIMITED AND CONTROLLED ENTITIES**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**FOR THE YEAR ENDED 30 JUNE 2018**

<i>In dollars</i>	<i>Note</i>	<b>2018</b>	<b>2017</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash	8	276,968	177,604
Trade and other receivables	10	918,026	1,556,835
Prepayments		158,408	107,824
Other current assets		-	-
<b>Total current assets</b>		<b>1,353,402</b>	<b>1,842,263</b>
<b>Non-current assets</b>			
Property, plant and equipment	11	291,456	203,324
Intangible assets	12	1,144,414	363,713
Other receivables	10	331,387	-
Investment in associate	20(b)	228,060	220,113
Financial assets	20(c,d)	19,499,218	19,026,938
Deferred tax assets		1,320	1,320
<b>Total non-current assets</b>		<b>21,495,855</b>	<b>19,815,408</b>
<b>Total Assets</b>		<b>22,849,257</b>	<b>21,657,671</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	13	872,618	807,715
Provisions	14	-	27,054
Employee benefit liabilities	15	258,794	368,743
Borrowings	16	-	2,653,461
Provision for income tax		-	-
<b>Total current liabilities</b>		<b>1,131,412</b>	<b>3,856,973</b>
<b>Non-current liabilities</b>			
Employee benefit liabilities	15	42,806	24,604
Borrowings	16	3,065,696	-
Deferred tax liabilities		3,208,384	3,271,841
<b>Total non-current liabilities</b>		<b>6,316,886</b>	<b>3,296,445</b>
<b>Total liabilities</b>		<b>7,448,298</b>	<b>7,153,418</b>
<b>Net assets/(liabilities)</b>		<b>15,400,959</b>	<b>14,504,253</b>
<b>Equity</b>			
Contributed equity	17	10,758,438	6,252,842
Reserves		-	-
Retained earnings/ (accumulated losses)		4,642,521	8,251,411
<b>Total equity</b>		<b>15,400,959</b>	<b>14,504,253</b>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes to the consolidated financial statements.*

**IQX LIMITED AND CONTROLLED ENTITIES**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30 JUNE 2018**

<i>In dollars</i>	Contributed equity	Option reserve	Retained earnings	Total
<b>Balance at 1 July 2017</b>	<b>6,252,842</b>	-	<b>8,251,411</b>	<b>14,504,253</b>
<b>Total comprehensive loss for the period</b>				
Loss for the period	-	-	(3,608,890)	(3,608,890)
Other comprehensive profit for the period	-	-	-	-
<b>Total comprehensive loss for the period</b>	-	-	<b>(3,608,890)</b>	<b>(3,608,890)</b>
<b>Transactions with owners recorded directly in equity</b>				
Conversion of notes previously classified as liability	3,001,000	-	-	3,001,000
Allotment of shares from employee share plan	3,960	-	-	3,960
Issue of convertible notes	1,664,068	-	-	1,664,068
Share issue cost	(163,432)	-	-	(163,432)
<b>Total transactions with owners recorded directly in equity</b>	<b>4,505,596</b>	-	-	<b>4,505,596</b>
<b>Balance at 30 June 2018</b>	<b>10,758,438</b>	-	<b>4,642,521</b>	<b>15,400,959</b>
<b>Balance at 1 July 2016</b>	<b>5,453,087</b>	<b>167,530</b>	<b>(5,966,976)</b>	<b>(346,359)</b>
<b>Total comprehensive loss for the period</b>				
Profit for the period	-	-	14,218,387	14,218,387
Other comprehensive income for the period	-	-	-	-
<b>Total comprehensive profit</b>	-	-	<b>14,218,387</b>	<b>14,218,387</b>
<b>Transaction with owners recorded directly in equity</b>				
Capital raising costs	(23,141)	-	-	(23,141)
Issued capital	822,896	-	-	822,896
Options expired during the year	-	(167,530)	-	(167,530)
<b>Total transactions with owners recorded directly in equity</b>	<b>799,755</b>	<b>(167,530)</b>	-	<b>632,225</b>
<b>Balance at 30 June 2017</b>	<b>6,252,842</b>	-	<b>8,251,411</b>	<b>14,504,253</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes to the consolidated financial statements.*

**IQX LIMITED AND CONTROLLED ENTITIES**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2018**

<i>In dollars</i>	<i>Note</i>	<b>2018</b>	<b>2017</b>
<b>Cash flows from operating activities</b>			
Receipts from customers		2,786,444	3,003,518
Payments to suppliers and employees		(6,941,379)	(3,934,428)
Interest received		2,686	1,522
Interest paid		(263,917)	(9)
Reversal of provision		27,054	
<b>Net cash used in operating activities</b>	<b>25</b>	<b>(4,389,112)</b>	<b>(929,397)</b>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment		(12,639)	(26,205)
Investment in associates		-	-
Investment in joint venture		-	-
Proceeds from disposal of financial assets		-	-
Payment for capital work in progress		-	-
Purchase of intangible assets		(58,885)	-
<b>Net cash used in investing activities</b>		<b>(71,524)</b>	<b>(26,205)</b>
<b>Cash flows from financing activities</b>			
Proceeds from issue of convertible notes, net of costs		4,560,000	662,129
Advances from related parties		-	-
Payment of capital raising cost		-	-
<b>Net cash generated from financing activities</b>		<b>4,560,000</b>	<b>662,129</b>
Net increase/(decrease) in cash and cash equivalents		99,364	(293,473)
Cash and cash equivalents at the beginning of the period		177,604	471,077
Effect of movements in exchange rates on cash held		-	-
<b>Cash and cash equivalents at the end of the period</b>	<b>8</b>	<b>276,968</b>	<b>177,604</b>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes to the consolidated financial statements.*

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**1. REPORTING ENTITY**

IQX Limited (“iQX” or the “Company”) is a for-profit company limited by shares which is incorporated and domiciled in Australia. These consolidated financial statements (“financial statements”) as at and for the year ended 30 June 2018 comprise of the Company and its subsidiaries (collectively referred to as the “Group”).

These financial statements were authorised for issue by the Board of Directors on 11 September 2018.

**2. STATEMENT OF COMPLIANCE**

The financial statements are general purpose financial statements which have been prepared in accordance with Australian Accounting Standards (“AASBs”) adopted by the Australian Accounting Standards Board (“AASB”) and the *Corporations Act 2001*. The financial statements comply with International Financial Reporting Standards (“IFRS”) adopted by the International Accounting Standards Board (“IASB”).

**3. GOING CONCERN**

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

As disclosed in the financial statements, the Group incurred a loss of \$3,608,890 and had net cash outflows from operating activities of \$4,389,112 for the year ended 30 June 2018.

However, the Directors believe that there are reasonable grounds to believe that the company will be able to continue as a going concern on the basis that the Group will begin to generate revenue through license procurement income.

Accordingly, the Directors believe that the Group will be able to continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report.

The financial report does not include any adjustments relating to the amounts or classification of recorded assets or liabilities that might be necessary if the Group were not to operate as a going concern.

**4. SIGNIFICANT ACCOUNTING POLICIES**

This section sets out the significant accounting policies upon which the interim financial statements are prepared as a whole. Specific accounting policies are described in their respective notes to the interim financial statements. This section also shows information on new accounting standards, amendments and interpretations, and whether they are effective in the current or later years.

**Basis of preparation**

These financial statements are presented in Australian dollars, which is the Company’s functional currency.

The Company is of a kind referred to in ASIC Corporations Instrument 2016/191 dated 1 April 2016 and in accordance with that instrument, all financial information presented in Australian dollars has been rounded to the nearest dollar unless otherwise stated.

The financial statements have been prepared under the historical cost convention, except for, the revaluation of available-for-sale financial assets, financial assets and liabilities at fair value through profit or loss, and derivative financial instruments.

The accounting policies have been consistently applied to all periods presented in these financial statements, unless otherwise stated.

#### **4. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

##### **Basis of consolidation**

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has the rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the consolidated entity. Losses incurred by the consolidated entity are attributed to the non-controlling interest in full, even if that results in a deficit balance.

##### **Foreign operations**

The assets and liabilities of foreign operations are translated into Australian dollars (AUD) at the exchange rate at the reporting date. The income and expenses of foreign operations are translated into AUD at the average exchange rate of the month in which the transaction occurs.

Foreign currency differences are recognised in other comprehensive income and accumulated in the foreign currency translation reserve.

When a foreign operation is disposed of in its entirety or partially such that control, significant influence or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.

##### **Goods and Services Tax ("GST") and Value Added Tax ("VAT")**

Revenues, expenses and assets are recognised net of the amount of respective GST or VAT, except where the amount of GST or VAT incurred is not recoverable from the relevant taxation authority. In these circumstances, the GST or VAT is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST or VAT receivable or payable. The net amount of GST or VAT recoverable from, or payable to, the taxation authority is included with other payables in the consolidated statement of financial position.

Cash flows are presented on a gross basis. The GST or VAT components of cash flows arising from investing or financing activities which are recoverable from, or payable to the relevant taxation authority, are presented as operating cash flows in the consolidated statement of cash flows.

##### **Uses of judgements and estimates**

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

#### 4. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### Use of judgements and estimates (continued)

###### (i) Judgements

Significant judgement has been made in respect to: (a) an absence of significant influence over related party investees; and (b) designation of investments as fair value through profit or loss.

###### (ii) Estimates

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements, including about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the year ending 30 June 2017 are included in the following notes:

- Note 20 – Investments.

###### (iii) Measurement of fair values

A number of the Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Group has an established control framework with respect to the measurement of fair values.

The financial reporting team regularly reviews significant unobservable inputs and valuation adjustments. If third party information is used to measure fair values, management assess the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring the fair value of an asset or a liability, the Group uses market observable data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability might be categorised in different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group categorises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

##### **New standards and interpretations not yet adopted**

A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after 1 July 2018 and have not been applied in preparing these financial statements. Those which may be relevant to the Group are set out below. The Group does not plan to adopt these standards early.

#### 4. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### New standards and interpretations not yet adopted (continued)

###### (i) AASB 9 Financial Instruments

AASB 9 *Financial Instruments* becomes mandatory for the Group's 2019 financial statements and includes changes to the classification and measurement of financial assets, including a new expected credit loss model for calculating impairment. It also includes a new hedge accounting model to simplify hedge accounting requirements and more closely align hedge accounting with risk management activities. The Company is in the process of assessing the impact of this new standard to its financial statements. The Company will apply the standard for the first time in the half-year results ended 31 December 2018.

###### (ii) AASB 15 Revenue from contracts with customers

AASB 15 *Revenue from Contracts* becomes mandatory for the Group's 2019 financial statements and outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers; and replaces AASB 111 *Construction Contract*, AASB 118 *Revenue*, Interpretation 13 *Customer Loyalty Programs*, Interpretation 15 *Agreements for Construction of Real Estate*, Interpretation 18 *Transfer of Assets from Customers* and Interpretation 131 *Revenue-Barter Transactions involving Advertising Services*. The core principle is that an entity recognises revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company is in the process of assessing the impact of this new standard to its financial statements. The Company will apply the standard for the first time in the half-year results ended 31 December 2018.

###### (iii) AASB 16 Leases

AASB 16 *Leases* becomes mandatory for the Group's 2020 financial statements and removes the classification of leases between finance and operating leases, effectively treating all leases as finance leases for the lessee. The purpose is to provide greater transparency of a lessee's financial leverage and capital employed. The Company has not yet determined the potential effect of this standard on the Company's future financial statements. The Company will adopt this standard from 1 July 2019.

#### 5. OPERATING SEGMENTS

The Group has identified operating segments based on internal reporting that is reviewed and used by the chief operating decision makers (the Group CEO and the Group Chief Financial and Operating Officer) in assessing the performance of the respective segments. The operating segments are identified by management based on the nature of services provided, with each operating segment representing a strategic business that serves a different segment of the market.

In year 2018 the Group has two revenue streams being: (1) financial services fees charged; and (2) office and shared services fees charged. Segment analysis of revenue is provided below.

Information on net profit and assets by segment is not provided to the chief operating decision makers.

<i>In dollars</i>	2018	2017
Fees – financial services	207,727	240,760
Asset related revenue	-	1,871,614
Office and shared services revenue	1,552,309	1,287,856
<b>Total revenue</b>	<b>1,760,036</b>	<b>3,400,230</b>

##### Information on geographical segments

One hundred percent of the Group's revenue, expenses and profit are derived in Australia.

##### Reliance on major customers

One hundred percent of the Group's revenue is derived from related parties.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**6. REVENUE**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Fees – financial services	207,727	240,760
Asset related revenue	-	1,871,614
Office and shared services revenue	1,552,309	1,287,856
<b>Total revenue</b>	<b>1,760,036</b>	<b>3,400,230</b>

**Significant accounting policies**

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. The Group recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits associated with the transaction will flow to the Group and specific criteria relating to the type of revenue as noted below, has been satisfied. Any consideration deferred is treated as the provision of finance and is discounted at a rate of interest that is generally accepted in the market for similar arrangements. The difference between the amount initially recognised and the amount ultimately received is interest revenue.

**Rendering of services**

Revenue in relation to rendering of services is recognised depending on whether the outcome of the services can be estimated reliably. If the outcome can be estimated reliably then the stage of completion of the services is used to determine the appropriate level of revenue to be recognised in the period. If the outcome cannot be reliably estimated, then revenue is recognised to the extent of expenses recognised that are recoverable.

**Asset related revenue**

Asset related revenue is recognised when it is received or when the right to receive payment is established.

**7. INCOME AND EXPENSES**

**(a) Other income**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Rebates	-	2,000
Interest income	2,695	1,522
Change in fair value of financial asset	71,598	19,000,000
<b>Total other income</b>	<b>74,293</b>	<b>19,003,522</b>

**(b) Finance costs**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Bank fees	10,819	2,940
Interest expense	494,163	445,077
<b>Total finance costs</b>	<b>504,982</b>	<b>448,017</b>

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**7. INCOME AND EXPENSES (CONTINUED)**

**(c) Employee benefits expenses**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Wages and salaries	1,697,687	1,272,846
Compulsory superannuation contributions	158,066	121,427
Increase in liability for annual leave	5,717	49,902
Increase in liability for long service leave	18,202	24,604
<b>Total employee benefit expense</b>	<b>1,879,672</b>	<b>1,468,779</b>

**(d) Other expenses**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Accounting and legal fees	56,265	85,031
Advertising and marketing	8,902	265,284
Insurance	154,736	109,474
Software and licensing	210,093	238,908
Travel and accommodation	4,806	21,537
Website maintenance	-	132,338
Other	1,002,847	640,145
<b>Total other expenses</b>	<b>1,437,649</b>	<b>1,492,717</b>

**8. CASH**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Bank balances	276,968	177,604

**Significant accounting policies**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**9. INCOME TAXES**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Profit/(loss)	(3,674,002)	17,492,126
Effective tax rate	27.5%	27.5%
	<b>(1,010,351)</b>	<b>4,810,335</b>
<b>Sub-total</b>		
Tax effect of:		
Expenditure not allowed for income tax purposes	(89,607)	123,298
Temporary differences not brought to account	54,429	15,854
Deferred tax assets not brought to account	980,417	(1,675,748)
<b>Income tax (income)/expense</b>	<b>(65,112)</b>	<b>3,273,739</b>

**Significant accounting policies**

**Current tax**

The income tax expense or benefit for the year is the tax payable on the current year's taxable income based on the application income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company's subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Current tax is recognised in profit or loss except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity respectively.

**Deferred tax**

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probably that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations when the Company is able to control the timing of the reversal of the temporary differences and it is probably that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to the offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity respectively.

**10. TRADE AND OTHER RECEIVABLES**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Other receivables	273,832	559,525
Related party payables	644,194	997,310
Bank guarantee <sup>1</sup>	331,387	-
<b>Total trade and other receivables</b>	<b>1,249,413</b>	<b>1,556,835</b>
Current	918,026	1,556,835
Non-current	331,387	-
<b>Total trade and other receivables</b>	<b>1,249,413</b>	<b>1,556,835</b>

<sup>1</sup> Provision of bank guarantee relating to the lease agreement for 85 Castlereagh Street, Sydney, NSW 2000.

**Significant accounting policies**

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. Trade receivables are generally due for settlement within 30-60 days. They are presented as current assets unless collection is not expected for more than 12 months after the reporting date.

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written off by reducing the carrying amount directly. The loss is recognised in profit or loss within other expenses. Subsequent recoveries of amounts previously written off are credited against other expenses in the profit or loss.

Other receivables are recognised at amortised cost, less any provision for impairment.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**11. PROPERTY, PLANT AND EQUIPMENT**

**Cost**

<i>In dollars</i>	Furniture, fixtures and fittings	Leasehold improvements	Plant and equipment	Total
Balance at 1 July 2016	46,247	125,891	78,258	250,396
Additions	26,627	20,393	7,053	54,073
<b>Balance at 30 June 2017</b>	<b>72,874</b>	<b>146,284</b>	<b>85,311</b>	<b>304,469</b>
Additions	12,233	155,838	70,801	238,872
Disposal	(31,328)	(143,202)	(7,204)	(181,734)
Effect of movement in foreign exchange	(3,968)	-	-	(3,968)
<b>Balance at 30 June 2018</b>	<b>49,811</b>	<b>158,920</b>	<b>148,908</b>	<b>357,639</b>

**Accumulated depreciation**

<i>In dollars</i>	Furniture, fixtures and fittings	Leasehold improvements	Plant and equipment	Total
Balance at 1 July 2016	6,475	19,874	20,968	47,317
Depreciation expense	6,581	32,006	15,241	53,828
<b>Balance at 30 June 2017</b>	<b>13,056</b>	<b>51,880</b>	<b>36,209</b>	<b>101,145</b>
Depreciation expense	7,070	11,135	17,721	35,926
Disposal	(7,670)	(57,987)	(5,219)	(70,876)
Effect of movement in foreign exchange	(12)	-	-	(12)
<b>Balance at 30 June 2018</b>	<b>12,444</b>	<b>5,028</b>	<b>48,711</b>	<b>66,183</b>

**Carrying amount**

<i>In dollars</i>	Furniture, fixtures and fittings	Leasehold improvements	Plant and equipment	Total
<b>Carrying balance at 30 June 2017</b>	<b>59,818</b>	<b>94,404</b>	<b>49,102</b>	<b>203,324</b>
<b>Carrying balance at 30 June 2018</b>	<b>37,367</b>	<b>153,892</b>	<b>100,197</b>	<b>291,456</b>

**11. PROPERTY, PLANT, AND EQUIPMENT (CONTINUED)**

**Significant accounting policies**

**Carrying value**

All property, plant and equipment are stated at historical cost less depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the business and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to the profit or loss during the reporting period.

**Depreciation**

Depreciation of assets is calculated using the straight-line method to allocate their cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements, the shorter lease term as follows:

- Leasehold improvements – 5 to 10 years
- Plant and equipment – 5 to 10 years
- Furniture, fittings and equipment – 10 to 20 years

**Impairment**

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

**Gains and losses on disposal**

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These are included in profit or loss.

**12. INTANGIBLE ASSETS**

<i>In dollars</i>	<b>Trademark</b>	<b>Website and software</b>	<b>Development costs</b>	<b>Total</b>
<b>Cost</b>				
Cost at 1 July 2016	-	48,842	-	48,842
Additions	4,000	123,504	205,503	333,007
<b>Balance at 30 June 2017</b>	<b>4,000</b>	<b>172,346</b>	<b>205,503</b>	<b>381,849</b>
Additions	-	983,000	244,305	1,227,305
<b>Balance at 30 June 2018</b>	<b>4,000</b>	<b>1,155,346</b>	<b>449,808</b>	<b>1,609,154</b>

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**12. INTANGIBLE ASSETS (CONTINUED)**

<i>In dollars</i>	Trademark	Website and software	Development costs	Total
<b>Accumulated Amortisation</b>				
Balance at 1 July 2016	-	-	-	-
Amortisation expense	-	18,136	-	18,136
<b>Balance at 30 June 2017</b>	<b>-</b>	<b>18,136</b>	<b>-</b>	<b>18,136</b>
Additions	-	77,338	-	77,338
Impairment	-	-	369,266	369,266
<b>Balance at 30 June 2018</b>	<b>-</b>	<b>95,474</b>	<b>369,266</b>	<b>464,740</b>

<i>In dollars</i>	Trademark	Website and software	Development costs	Total
<b>Carrying amounts</b>				
<b>Balance at 30 June 2017</b>	<b>4,000</b>	<b>154,210</b>	<b>205,503</b>	<b>363,713</b>
<b>Balance at 30 June 2018</b>	<b>4,000</b>	<b>1,059,872</b>	<b>80,542</b>	<b>1,144,414</b>

**Significant accounting policies**

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition.

Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss and other comprehensive income when the asset is derecognised.

**Amortisation**

Intangible assets with finite lives are amortised over the useful economic life. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates and adjusted on a prospective basis. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit or loss and other comprehensive income as the expense category that is consistent with the function of the intangible assets.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

**12. INTANGIBLE ASSETS (CONTINUED)**

**Impairment**

Intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use.

**Website and software**

Costs incurred in acquiring website software and licenses that will contribute to future financial benefits through revenue generation and/or cost reduction are capitalised to software and systems. Costs capitalised include external direct costs of materials and service and direct payroll and payroll related costs of employees' time spent on the project. Amortisation is calculated on a straight-line basis over periods generally ranging from three to five years

Website development costs include only those directly attributable to the development phase and are only recognised following completion of technical feasibility and where the business has an intention and ability to use the asset.

**Research and development costs**

Research expenditure is recognised as an expense as incurred.

Development costs include externally acquired and internally generated costs of materials and services, which can be directly attributable to the development activities of acquiring or generating an intangible asset.

Costs incurred on development projects (relating to the design and testing of new or improved intangible assets) are recognised only when it is probable that the future economic benefits that are attributable to the asset will flow to the Group, the cost of the asset can be measured reliably, technical and commercial feasibility of the asset for sale or use have been established, and the Group intends and is able to complete the intangible asset and either use it or sell it.

Capitalised development costs are recorded as an intangible asset and amortised from the point at which the asset is ready for use on a straight-line basis over its useful life. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

**13. TRADE AND OTHER PAYABLES**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Trade payables	429,979	342,791
Sundry payables and accrued expenses	169,271	152,444
Related party payables	273,368	312,480
<b>Total trade and other payables</b>	<b>872,618</b>	<b>807,715</b>
Current	872,618	805,715
Non-current	-	-
<b>Total trade and other payables</b>	<b>872,618</b>	<b>807,715</b>

**Significant accounting policies**

Trade and other payables represent liabilities for goods and services provided to the business prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**14. PROVISIONS**

<i>In dollars</i>	<b>Make good</b>	<b>Total</b>
Balance at 1 July 2017	27,054	-
Provisions made during the period	(27,054)	27,054
<b>Total provisions at 30 June 2018</b>	<b>-</b>	<b>27,054</b>

**Significant accounting policies**

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit or loss and other comprehensive income net of any reimbursement.

**Make-good provisions**

A make good provision is recognised for the costs of restoration or removal in relation to plant and equipment and site leases where there is a legal or constructive obligation. The provision is initially recorded when a reliable estimate can be determined and discounted to present value. The unwinding of the effect of discounting on the provision is recognised as a finance cost.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the liability. The increase in the provision due to the passage of time is recognised as interest expense.

**15. EMPLOYEE BENEFIT LIABILITIES**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Liability for annual leave		
Opening balance	101,182	51,281
Additional provision	120,918	74,324
Utilisation	(115,200)	(24,423)
Closing Balance	106,900	101,182
Liability for long service leave		
Opening balance	24,604	-
Additional provision	18,202	24,604
Utilisation	-	-
Closing Balance	42,806	24,604
Liability for superannuation	54,436	48,498
Liability for bonus	-	-
Liability for payroll	97,458	219,063
<b>Total employee benefit liabilities</b>	<b>301,600</b>	<b>393,347</b>
Current	258,794	368,743
Non-current	42,806	24,604
<b>Total employee benefit liabilities</b>	<b>301,600</b>	<b>393,347</b>

**15. EMPLOYEE BENEFIT LIABILITIES (CONTINUED)**

**Significant accounting policies**

Employee benefits represents amounts accrued for employee payroll, superannuation, annual leave and long service leave.

The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Based on past experience the Group does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled in the next 12 months. However, these amounts must be classified as current liabilities since the Group does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.

The Group recognises a liability for long service leave and annual leave measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods to service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currencies that match, as closely as possible, the estimated future cash outflows.

**16. BORROWINGS**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Convertible notes	3,065,696	2,653,461
Current	-	2,653,461
Non-current	3,065,696	-
<b>Total convertible notes</b>	<b>3,065,696</b>	<b>2,653,461</b>

**Significant accounting policies**

Convertible notes are separated into liability and equity components based on the terms of the contract.

On issuance of the convertible notes, the fair value of the liability component is estimated using a market rate for an equivalent non-convertible instrument. This amount is classified as a financial liability at amortised cost (net of transaction costs) until it is extinguished on conversion or redemption.

The remainder of the proceeds is allocated to the conversion option that is recognised and included in equity. Transaction costs are deducted from equity. The carrying amount of the conversion option is not re-measured in subsequent years.

Transaction costs are apportioned between the liability and equity components of the convertible notes based on the allocation of proceeds to the liability and equity components when the instruments are initially recognised.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**17. ISSUED CAPITAL**

	Number of shares	\$
In issue at 1 July 2016	110,210,000	5,453,087
Allotment of shares from exercise of Loyalty options & economic options	7,625,900	850,180
Share and notes issue costs	-	(50,425)
<b>In issue at 30 June 2017</b>	<b>117,835,900</b>	<b>6,252,842</b>
Conversion of notes previously classified as liability	8,826,472	3,001,000
Allotment of shares from employee share plan	396,000	3,960
Issue of convertible bond	-	1,664,068
Share and note issue costs	-	(163,432)
<b>In issue at 30 June 2018</b>	<b>127,058,372</b>	<b>10,758,438</b>

All ordinary shares rank equally with regard to the Company's residual assets. The holders of these shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at general meetings of the Company.

The Company does not have authorised capital or par value in respect of its shares. All issued shares are fully paid.

**(i) 10c Loyalty options**

There are no Loyalty options outstanding at 30 June 2017. At 30 June 2016, the Company had 13,950,000 Loyalty options outstanding to be exercised at 10c each expiring on the three-year anniversary of the admission to the Official List of the NSX. A total 6,750,000 options were exercised during the current period, with the remaining 7,200,000 options expiring during the current period.

**(ii) 20c Economos options**

There are no Economos options outstanding at 30 June 2017. At 30 June 2016, the Company had 1,117,000 Economos options outstanding to be exercised at 20c each expiring on the three-year anniversary of the admission to the Official List of the NSX. A total of 875,900 options were exercised during the current period, with the remaining 241,100 options expiring during the current period.

**(iii) Movements in options**

	Number of options	Total \$	Weighted average price per option
Options in issue at 1 July 2016	15,067,000	1,618,400	\$0.11
Options exercised during the period	(7,625,900)	(850,180)	\$0.11
Options expired during the period	(7,441,100)	(768,220)	\$0.10
<b>Options in issue at 30 June 2017</b>	<b>-</b>	<b>-</b>	<b>-</b>

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**17. ISSUED CAPITAL (CONTINUED)**

**(iv) Movements in convertible notes**

On the 25 January 2018, 8,826,472 convertible notes were converted to ordinary share, at an issue price of \$0.34 per share.

**(v) Shares issued under employee share plan**

On the 28 March 2018, 396,000 fully paid ordinary shares were allotted under the employee share plan, at an issue price of \$0.01 per share.

**Dividends**

No dividends were declared or paid by the Company for the year (2017: nil).

**Significant accounting policies**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Transaction costs are the costs that are incurred directly in connection with the issue of those equity instruments and which would not have been incurred had those instruments not been issued.

**18. EARNINGS PER SHARE (EPS)**

The calculation of basic earnings per share has been based on the following loss attributable to ordinary shareholders and weighted-average number of ordinary shares outstanding.

**(Loss)/profit attributable to ordinary shareholders**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
(Loss)/profit for the period attributable to owners of IQX Limited	(3,608,890)	14,218,387
Weighted-average number of ordinary shares at the end of the period	123,293,277	116,394,292
Basic (loss)/earning per share	(2.93)	12.22
Diluted (loss)/earning per share	(2.93)	12.22

Basic earnings per share is calculated as earnings for the period attributable to the Company over the weighted average number of shares.

Diluted earnings per share is calculated as earnings for the period attributable to the Company over the weighted average number of shares which has been adjusted to reflect the number of shares which would be issued if outstanding options were to be exercised.

There were no outstanding options at 30 June 2018 and 30 June 2017.

## **19. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT**

### **Accounting classifications and fair values**

The Group has financial assets of cash and cash equivalents, trade and other receivables, and shares in a listed company. The shares in a listed company are valued at fair value. The remaining financial assets are not measured at fair value, and the carrying amount is a reasonable approximation of fair value at 30 June 2018.

The Group has financial liabilities of trade and other payables. These financial liabilities are not measured at fair value, and the carrying amount is a reasonable approximation of fair value at 30 June 2018.

### **Financial risk management**

There have been no substantive changes in the types of risk the Group is exposed to, how these risks arise, or the Board's objectives, policies and processes for managing or measuring the risk from the previous period. The Group has exposure to the following risk arising from financial instruments:

- credit risk – refer (ii)
- liquidity risk – refer (iii)
- market risk – refer (iv)

#### **(i) Risk management framework**

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The Board of Directors has established the Audit and Risk Management Committee, which is responsible for developing and monitoring the Group's risk management policies. The committee reports regularly to the Board of Directors on its activities.

The Group's risk management policies are established to identify and analyse the risk faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities. The Group, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all workplace participants understand their roles and obligations.

The Board of Directors has also established a Finance Committee, consisting of senior executives of the Group, which meets on a regular basis to analyse financial risk exposure and to evaluate treasury management strategies in the context of the most recent economic conditions and forecasts. The finance committee's overall risk management strategy seeks to assist the Group in meeting its financial targets, whilst minimising potential adverse effects on financial performance. The finance committee operates under policies approved by the Board of Directors.

#### **(ii) Credit risk**

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the Group.

The Group has no significant concentration of credit risk with respect to any single counterparty or group of counterparties other than those receivables specifically provided for and mentioned within note 10.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**19. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (CONTINUED)**

**Trade and other receivables**

The main source of credit risk to the Group is considered to relate to the class of assets described as trade and other receivables. Trade and other receivables that are neither past due or impaired are considered to be of high credit quality. Aggregates of such amounts are detailed in note 10.

No collateral is held over other receivables.

**Impairment**

The aging of the trade and other receivables that were not impaired as at 30 June 2018 are set out in the following table.

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Neither past due nor impaired	918,026	889,327
30 to 90 days past due but not impaired	-	-
Over 90 days due but not impaired	-	667,508
<b>Total trade and other receivables</b>	<b>918,026</b>	<b>1,556,835</b>

**Cash and cash equivalents**

The Group held cash and cash equivalents of \$276,968 at 30 June 2018. The cash and cash equivalents are held with bank and financial institution counterparties, which are rated AA- to AA+, based on rating agency Standard and Poor's ratings.

**(iii) Liquidity risk**

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The Group aims to maintain cash at a level appropriate to fund operations. At 30 June 2018, the expected cash flows from trade and other receivables maturing within two months were \$254,718.

**Non-derivative financial liabilities**

<i>In dollars</i>	<b>Within 1 year</b>		<b>1 to 5 years</b>		<b>Over</b>	<b>5</b>	<b>Total</b>	
	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>
Trade and other payables	872,618	807,715	-	-	-	-	872,618	807,715
<b>Total non-derivative financial liabilities</b>	<b>872,618</b>	<b>807,715</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>872,618</b>	<b>807,715</b>

**(ii) Market risk**

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The Company is not sensitive to changes in foreign exchange rates, interest rate and equity prices.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**19. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (CONTINUED)**

**(iii) Currency risk**

The Group's exposure to foreign currency risk is limited due to the natural hedge afforded to the Group by purchasing and selling in local currency in all countries in which it operates. The Group does not hold any foreign currency contracts.

**20. INVESTMENTS**

The percentage ownership interest is equivalent to the percentage voting rights for all investments.

**(a) Interests in subsidiaries and associates**

Entity name	Country of incorporation	Ownership interest 2018	Ownership interest 2017
<b>Subsidiaries</b>			
iQX Investment Services Pty Ltd	Australia	100%	100%
The iQ Group Global Pty Ltd	Australia	100%	100%
iQ Capital Partners (No. 1) Pty Ltd	Australia	100%	100%
iQ Series 8 Life Science Fund (Global) Pty Ltd	Australia	100%	100%
iQ Series 8 GP	Cayman Islands	100%	100%
<b>Associates</b>			
New Frontier Holdings LLC ("New Frontier")	USA	20%	20%
Nereid Enterprises Pty Ltd	Australia	20%	20%
Nereid Enterprises LLC	USA	20%	20%

Nereid Enterprises Pty Ltd provides corporate events and promotional services to the healthcare industry and related parties of iQX Limited.

None of the associates are listed on a stock exchange. The investments in associates is equity accounted using audited financial information.

**(b) Investment in associates accounted for using equity method**

<i>In dollars</i>	2018	2017
<b>(i) Summararised statement of comprehensive income</b>		
Revenue	54,101	67,027
Loss after tax	(198,283)	(152,778)
Other comprehensive income /(loss)	1,206	(1,921)
Total comprehensive loss	(197,077)	(155,699)
Dividend received from associate	-	-
<b>(ii) Reconciliation to carrying amount</b>		
Net asset balance at start of period	1,100,565	1,243,277
Additional investment	68,386	-
Profit/(loss) for the period	(28,653)	(142,712)
Other comprehensive income	-	-
<b>Net asset balance at end of period</b>	<b>1,140,298</b>	<b>1,100,565</b>
Consolidated entity's share in %	20%	20%
Consolidated entity's share at acquisition	228,060	220,113
Adjustment posted in following period	-	-
<b>Consolidated entity's share at reporting date</b>	<b>228,060</b>	<b>220,113</b>

**20. INVESTMENTS (CONTINUED)**

**(c) Financial assets carried at fair value through profit or loss – designated on initial recognition**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Shares in unlisted companies	19,471,598	19,000,000

**(d) Available for sale financial assets**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Shares in listed companies	11,250	11,250
Investments in unit trusts	16,370	15,688
<b>Total available for sale financial assets</b>	<b>27,620</b>	<b>26,938</b>

**Significant accounting policies**

**Subsidiaries**

Subsidiaries are all entities (including structured entities) over which the parent has control. Control is established when the parent is exposed to or has rights to variable rates of returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity.

**Associates**

Associates are all entities over which the Group has significant influence but not control, generally accompanying a shareholding between 20% and 50% of the voting rights. Investments in associates are accounted for in the Group's financial statements using the equity method of accounting, after initially being recognised at cost.

The Group's share of the associates post-acquisition profits or losses are recognised in the statement of profit or loss, and its share of post-acquisition movements in reserves is recognised in reserves. The cumulative post acquisition movements are adjusted against the carrying amount of the investment. Dividends receivable from associates reduce the carrying amount of the investment.

When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any unsecured receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the associate.

**Financial assets carried at fair value**

Other financial assets are carried at fair value, or the price the Group would receive to sell an asset or would have to pay to transfer a liability in an orderly (i.e. unforced) transaction between independent, knowledgeable and willing market participants at the measurement date.

The Group discloses the fair value measurements by level using the following fair value measurement hierarchy:

- quoted prices (unadjusted) in active markets for identical assets (level 1);
- inputs other than quoted prices included within level 1 that are observable that are observable for the asset, either directly (as prices) or indirectly (derived from prices) (level 2); and
- inputs for the asset or liability that are not based on observable market data (unobservable inputs) (level 3).

**20. INVESTMENTS (CONTINUED)**

**Shares in listed companies and unit trusts**

Shares in listed companies and unit trusts are initially recognised at cost at accounting trade date. Shares in listed companies and unit trusts that have an interest in listed companies are subsequently carried at fair value using level 1 fair value measurement inputs. Any subsequent increase or decrease in fair value is recognised in other comprehensive income.

Gains and losses arising from shares in listed companies are only recognised in the profit or loss when they are sold or impaired.

**Shares in unlisted companies**

The Group designate share in unlisted companies as fair value through profit or loss where performance is evaluated on a total return basis comprising both income and fair value; and where fair value can be reliably measured. Shares in unlisted companies carried at fair value through profit or loss are initially recognised at cost at accounting trade date. They are subsequently carried at fair value using level 2 and level 3 fair value measurement inputs. Any subsequent increase or decrease in fair value is recognised in profit or loss. Gains and losses arising from shares in unlisted companies are only recognised in the profit or loss when they are sold or impaired.

**21. FAIR VALUE MEASUREMENT**

**Fair value hierarchy**

The following tables detail the Group's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical markets for identical assets or liabilities that the entity can access at the measurement date;

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3: Unobservable inputs for the asset or liability.

**Consolidated - 2018**

<i>In dollars</i>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets</b>				
Shares in unlisted companies	-	19,471,598	-	19,471,598
Shares in listed companies	11,250	-	-	11,250
Investments in quoted unit trusts	16,370	-	-	16,370
<b>Total assets</b>	<b>27,620</b>	<b>19,471,598</b>	<b>-</b>	<b>19,499,218</b>
<b>Liabilities</b>				
Convertible notes	-	3,065,696	-	3,065,696
<b>Total liabilities</b>	<b>-</b>	<b>3,065,696</b>	<b>-</b>	<b>3,065,696</b>

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**21. FAIR VALUE MEASUREMENT (CONTINUED)**

**Consolidated - 2017**

<i>In dollars</i>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets</b>				
Shares in unlisted companies	-	19,000,000	-	19,000,000
Shares in listed companies	11,250	-	-	11,250
Investments in quoted unit trusts	15,688	-	-	15,688
<b>Total assets</b>	<b>26,938</b>	<b>19,000,000</b>	<b>-</b>	<b>19,026,938</b>
<b>Liabilities</b>				
Convertible notes	-	2,653,461	-	2,653,461
<b>Total liabilities</b>	<b>-</b>	<b>2,653,461</b>	<b>-</b>	<b>2,653,461</b>

There were no transfers between levels during the financial year.

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

The gain recognised in profit or loss for the period from level 2 valuations is \$471,598 (2017: 19,000,000).

**Valuation techniques for fair value measurements categorised within level 2**

**Financial assets carried at fair value through profit or loss (\$19,000,000)**

The shares in unlisted company were revalued on 30 June 2017 based on internal assessments performed by management, with reference to independent private placement investments made in the vehicle.

The planned listing of the underlying investment will entail 12% of the total equity of which iQX Limited owns 19% of the issued capital being listed. Independent pre-ipo investors have valued the shares in the underlying entity at \$100,000,000.

**Significant accounting policies**

Assets and liabilities measured at fair value are classified into three levels using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**22. OPERATING LEASES**

The Group lease an office facility under an operating lease. The lease is non-cancellable and run for a period of 5 years, with an option to renew the lease after that date. Contingent rental provisions within the lease agreement require that the minimum lease payments shall be increased by 4.25% per annum. The lease allows for subletting of all lease areas.

**Future minimum lease payments**

As at 30 June 2018, the future minimum lease payments under non-cancellable leases were payable as set out in the following table.

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Less than one year	113,305	112,165
Between one and five years	618,998	-
More than five years	-	-
<b>Total future minimum lease payments</b>	<b>732,303</b>	<b>112,165</b>

**23. CONTINGENCIES**

The Group has no contingent liabilities or assets as at the reporting date (2017: None).

**24. TRANSACTIONS WITH RELATED PARTIES**

**(i) Parent and ultimate controlling party**

iQX Limited was the parent and ultimate controlling party of the Group throughout the year ended 30 June 2018.

**(ii) Key management personnel compensation**

The key management personnel compensation is set out in the table below.

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
Short-term employee benefits	720,649	592,408
Post-employment benefits	68,461	52,927
Share based payment	3,960	-
<b>Total key management personnel compensation</b>	<b>793,070</b>	<b>645,335</b>

Compensation of the Group's key management personnel includes salaries and non-cash benefits. Executive officers also participate in the Group's employee incentive plan.

Further details of key management personnel compensation are included in the Remuneration Report within the Directors' Report.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**24. TRANSACTIONS WITH RELATED PARTIES (CONTINUED)**

**(iii) Transactions with other related parties**

The Group transacted with the following related companies. Transactions with other related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

Entity name	Relationship
iQnovate Ltd and controlled entities	Common directorship and/ key management personnel
iQ3Corp Ltd and controlled entities	Common directorship and/ key management personnel
Nereid Enterprises Pty Ltd	An Associate with common directorship and/key management personnel

The aggregate value of transactions and outstanding balances relating to subsidiaries and associates are set out in the following table.

<i>In dollars</i>	2018	2017
Financial services fees received from related parties	207,727	240,760
Asset related revenue received from related parties	-	1,871,614
Shared services fees received from related parties	1,552,309	1,287,856
<b>Change in fair value of financial asset held in related parties</b>	-	<b>19,000,000</b>
<b>Total revenue and other income received from related parties</b>	<b>1,760,036</b>	<b>22,400,230</b>
Payment of shared services fees to related parties	636,253	332,251
Other transaction and administrative costs paid to related parties	190,839	933,784
<b>Total costs paid to related parties</b>	<b>827,092</b>	<b>1,266,035</b>
Trade payable accounts with related parties	(273,368)	(312,480)
Trade receivable accounts with related parties	644,194	997,310
<b>Net trade receivable/(payable) from related parties</b>	<b>370,826</b>	<b>684,830</b>

iQ3 an related party sold it's Capital Labs platform product to iQX, for \$983,000. This product was developed by iQ3 with the intention to be onsold.

**(iv) Details of associates**

Name	Country of incorporation	Ownership interest 30 June 2018	Ownership interest 30 June 2017
New Frontier Holdings LLC	USA	20%	20%
Nereid Enterprises Pty Ltd	AUS	20%	20%
Nereid Enterprises LLC	USA	20%	20%

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**25. RECONCILIATION OF CASH FLOWS FROM OPERATING ACTIVITIES**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
<b>Cash flows from operating activities</b>		
(Loss)/profit for the period	(3,608,890)	14,218,387
Adjustments for:		
Depreciation	113,265	71,150
Interest on convertible notes	290,546	444,538
Impairment of intangible assets	369,266	-
Reversal of provision	27,054	-
Capital raising costs written off	-	337,472
Revaluation of financial assets through profit or loss	-	(19,000,000)
Share of loss from associated companies	28,653	57,959
	<b>(2,780,106)</b>	<b>(3,870,494)</b>
Changes in:		
Trade and other receivables	1,181,791	(738,735)
Prepayments	(50,584)	65,383
Trade and other payables	(2,648,466)	2,688
Employee benefits	(91,747)	342,066
Deferred tax	-	3,271,841
Tax payable	-	(2,146)
	<b>(1,609,006)</b>	<b>2,941,096</b>
<b>Net cash used in operating activities</b>	<b>(4,389,112)</b>	<b>(929,397)</b>

**26. AUDITORS' REMUNERATION**

<i>In dollars</i>	<b>2018</b>	<b>2017</b>
<b>Audit and review services</b>		
Auditors of the Group at June 2018 – RSM Australia Partners	31,500	20,000
Auditors of the Group at December 2017 – RSM/Fortunity	5,800	4,000
Other auditors	-	-
<b>Other services</b>		
Auditors of the Group at June 2017 – RSM Australia Partners	-	10,000
Auditors of the Group at December 2016 – Fortunity	-	-
Other auditors	-	-

**27. SUBSEQUENT EVENTS**

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors to affect significantly the operations or state of affairs of the Group in future financial years.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**DIRECTOR'S DECLARATION**  
**FOR THE YEAR ENDED 30 JUNE 2018**

1. In the opinion of the Board of Directors of iQX Limited ("the Company"):
  - a. the consolidated financial statements and notes that are set out on pages 23 to 52 are in accordance with the *Corporations Act 2001*, including:
    - I. giving a true and fair view of the financial position as at 30 June 2018 of the Company and its controlled entities ("the Group") and of the Group's performance for the financial year ended on that date; and
    - II. complying with Australian Accounting Standards and the *Corporations Regulations 2001*; and
  - b. there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
2. The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the chief executive officer and chief financial officer for the financial year ended 30 June 2018.
3. The Directors draw attention to note 2 to the interim consolidated financial statements, which includes a statement of compliance with International Financial Reporting Standards.

Signed in accordance with a resolution of Directors.



**Dr George Syrmalis**  
**Executive Director and Chief Executive Officer**

Sydney

28<sup>th</sup> September 2018

## INDEPENDENT AUDITOR'S REPORT To the Members of IQX Ltd

### Opinion

We have audited the financial report of IQX Ltd. (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2018, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion the accompanying financial report of the Group is in accordance with the Corporations Act 2001, including:

- (i) giving a true and fair view of the Group's financial position as at 30 June 2018 and of its financial performance for the year then ended; and
- (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.

### Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter	How our audit addressed this matter
<p><b>Fair value of Investment in LSB D</b> Refer to Note 21 in the financial statements</p>	
<p>The company designated its investment in Life Science Biosensor Diagnostic Limited as fair value on the basis of election on initial recognition.</p> <p>The fair value of the investment has been determined by management to be \$19,000,000 and is based on level 2 inputs from a valuation model that is based on external independent capital raisings.</p> <p>The designation of the investment and the valuation of the investment are matters which management has exercised judgement.</p>	<p>Our audit procedures in relation to the classification and valuation of the investment included:</p> <ul style="list-style-type: none"> <li>• Reviewing managements documented judgements of the application of AASB 139 <i>Financial Instruments: Recognition and Measurement</i> in relation to designating an equity investment as fair value.</li> <li>• Assessing managements valuation methodology and model with the firm’s internal valuation specialists.</li> <li>• Substantiating inputs into the valuation model by verifying independent capital raising transactions.</li> </ul>
<p><b>Carrying value of internally developed and acquired intangible assets</b> Refer to Note 12 in the financial statements</p>	
<p>The closing net book value of all internally developed and acquired intangible assets was \$1,144,414. The costs of building applications and web-site platforms are capitalised as intangible assets, where the expenditure demonstrable value and the technical and commercial feasibility is assured.</p> <p>Management has to exercise judgement in determining which costs can be capitalised and when performing an impairment review if impairment indicators are identified. The materiality of judgements involved has caused us to identify this as key audit risk.</p>	<p>Our audit procedures in relation to the carrying value of internally developed and acquired intangible assets included:</p> <ul style="list-style-type: none"> <li>• Reviewing management’s identification of the development projects being undertaken, and their assessment of whether they meet the criteria for recognition as intangible assets in accordance with AASB 138 <i>Intangible Assets</i>.</li> <li>• Testing amounts capitalised in the period to assess whether expenses incurred were directly attributable to the projects identified, and therefore eligible for capitalisation.</li> </ul>

### Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2018 but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of the Directors for the Financial Report**

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

### **Auditor's Responsibilities for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: [http://www.auasb.gov.au/auditors\\_responsibilities/ar2.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar2.pdf).

This description forms part of our auditor's report.

### **Report on the Remuneration Report**

#### *Opinion on the Remuneration Report*

We have audited the Remuneration Report included in pages 9 to 14 of the directors' report for the year ended 30 June 2018.

In our opinion, the Remuneration Report of IQX Ltd., for the year ended 30 June 2018, complies with section 300A of the Corporations Act 2001.

#### *Responsibilities*

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



**RSM Australia Partners**



**David Talbot**

Partner

Sydney, 28 September 2018

## NSX ADDITIONAL INFORMATION

Additional information required by the NSX and not disclosed elsewhere in this report is set out below. The information is current as at 19 August 2018.

### SUBSTANTIAL SHAREHOLDERS

The number of shares held by substantial shareholders and their associates are set out below:

Shareholders grouped by common controllers	Number of Ordinary shares held	% of total ordinary shares
<b>(i) Ruminare Group</b>		
Ruminare Investments Pty Ltd	15,228,572	11.99%
TTS Two Investments Pty Ltd	2,900,000	2.28%
Anthony Tsigounis Pty Ltd	200,000	0.16%
<b>Total Ruminare Group</b>	<b>18,328,572</b>	<b>14.43%</b>
<b>(ii) Life Science Group</b>		
Life Science Investments Pty Ltd	6,000,000	4.72%
Zero Hedge Investments Pty Ltd	5,856,000	4.61%
Biotechnology Holdings Pty Ltd	4,261,112	3.35%
<b>Total Life Science Group</b>	<b>16,117,112</b>	<b>12.68%</b>
<b>(iii) Abiogenesis Pty Ltd</b>	<b>15,600,000</b>	<b>12.28%</b>
<b>(iv) Agparaskevi Group</b>		
Agparaskevi Pty Ltd	8,000,000	6.30%
Babi Holdings Pty Ltd	4,000,000	3.15%
<b>Total Agparaskevi Group</b>	<b>12,000,000</b>	<b>9.45%</b>
<b>(v) Adaptive Radiation Group</b>		
Adaptive Radiation Pty Ltd	8,888,888	7.00%
Sequential Investments Pty Ltd	1,600,000	1.26%
<b>Total Adaptive Radiation Group</b>	<b>10,488,888</b>	<b>8.26%</b>
<i>Total of substantial shareholders</i>	<i>72,534,572</i>	<i>57.09%</i>

### TEN LARGEST SHAREHOLDERS

Shareholder	Number of ordinary shares held	% of total ordinary shares
ABIOWISES PTY LTD	15,600,000	12.28%
RUMINATE INVESTMENTS PTY LTD	15,228,572	11.98%
ADAPTIVE RADIATION PTY LTD	8,888,888	7.00%
AGPARASKEVI PTY LTD <AGPARAEKEVI A/C>	8,000,000	6.30%
LIFE SCIENCE INVESTMENTS PTY LTD <LIFE SCIENCE SUPER FUND A/C>	6,000,000	4.72%
ZERO HEDGE INVESTMENTS PTY LTD <ZERO HEDGE INVESTMENTS A/C>	5,856,000	4.61%
BIOTECHNOLOGY HOLDINGS PTY LTD <BIOTECHNOLOGY A/C>	4,261,112	3.35%
BABI HOLDINGS PTY LTD <CLT SUPER FUND A/C>	4,000,000	3.15%
TTS TWO INVESTMENTS PTY LTD <TTS DISCRETIONARY A/C>	2,900,000	2.28%
PRIORITY ONE GROUP PTY LTD <THE UTOPIA INVESTMENT A/C>	2,352,941	1.85%
<b>Total securities of top 10 holdings</b>	<b>73,087,751</b>	<b>57.52%</b>

### Distribution of equity security holders

Category	Holders	Ordinary shares	%
1 – 1,000	-	-	0.00%
1,001 – 5,000	2	6,000	0.00%
5,001 – 10,000	9	88,000	0.07%
10,001 – 100,000	109	5,778,706	4.55%
100,001 and over	103	121,185,666	95.38%
<b>Total</b>	<b>194</b>	<b>127,058,372</b>	<b>100.00%</b>

### Shareholders with less than marketable parcel

There are no shareholders with an unmarketable parcel of shares.

This is based on a closing price of \$0.32 per share as at 21 August 2018.

### Shares subject to escrow

There is no security class subject to escrow as at 19 August 2018.

### Unquoted equity securities

There are no unquoted redeemable preference shares or redeemable convertible notes on issue.

**IQX LIMITED AND CONTROLLED ENTITIES**  
**NSX ADDITIONAL INFORMATION**  
**FOR THE YEAR ENDED 30 JUNE 2018**

**SECURITIES EXCHANGE**

The Company is listed on the National Securities Exchange of Australia. The Home exchange is Sydney.

**ON-MARKET BUY-BACK**

There is no current on-market buy-back.

**HISTORICAL SUMMARY TABLE**

Share performance				Financial performance A\$ million			
Period	Closing share price at 30 June	Dividend per share	EPS (cents)	Revenue	Profit/(loss) after tax	Assets	Liabilities
FY2018	\$0.32	NIL	(2.93)	\$1.8	(\$3.6)	\$22.8	\$7.4
FY2017	\$0.40	NIL	12.22	\$3.4	\$14.2	\$21.6	\$7.2
FY2016	\$0.43	NIL	(2.26)	\$0.5	(\$2.3)	\$2.7	\$3.0
FY2015	\$0.65	NIL	(1.27)	\$0.8	(\$1.3)	\$1.7	\$0.2
FY2014	\$0.65	NIL	(1.38)	-	(\$1.2)	\$1.6	\$0.2

**WAIVERS**

There are no arrangements where: (a) the Director's have agreed to waive any emoluments; or (b) where a shareholder has waived or agreed to waive any dividends.

**SIGNIFICANT CONTRACTS WITH DIRECTORS, CHILD ENTITIES OR CONTROLLING SHAREHOLDERS**

Refer to note 24 of the Notes to the Consolidated Financial Statements, for details of material related party transactions.

**DIRECTOR AND OFFICERS INTERESTS**

Refer to note 7 of the Remuneration Report, which forms part of the Annual Report, for details of Director and Officer interests.

**OTHER**

There are no period's unexpired of any service contract of any Director proposed for election at the forthcoming annual general meeting.